iShares Biotechnology ETF Newsroom

Looking At Gilead Sciences's Recent Unusual Options Activity

Benzinga04:15

'ADA Advises Against Using Compounded GLP-1 RA Medications' - Medscape

Benzinga01:11

European Stocks Will See Downtrend Mid-year 2025 Before Recovery

Seeking Alpha00:49

Sector Update: Health Care Stocks Decline Premarket Tuesday

MT NewswiresDec 3 22:18

Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance

BenzingaDec 3 22:16

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Ahead of October JOLTS Report

MT NewswiresDec 3 21:34

Gilead Sciences Ticks Upward for the Eight Consecutive Session

Seeking AlphaDec 3 03:28

10 Health Care Stocks With Whale Alerts In Today's Session

BenzingaDec 3 01:35

Sector Update: Health Care Stocks Mixed Pre-Bell Monday

MT NewswiresDec 2 22:14

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Monday Ahead of Week Promising Crucial Economic Data

MT NewswiresDec 2 21:37

The strongest competitor's data is not good, will the 'weight-loss duo' continue to dominate?

Analysts believe that if Amgen's weight loss drug could achieve a 20% weight loss effect a few years ago, it would have been the best among similar products, but now Eli Lilly and Co and Novo-Nordisk A/S pipeline drugs may achieve or exceed a 25% weight loss effect. Currently, dozens of pharmaceutical companies are actively entering the weight loss drug market, but none have shown the potential to truly challenge the 'weight loss giants'.

wallstreetcnDec 1 12:38

Barclays's 'Bang-for-the-buck' Tail Hedging ETFs: HYG, XLF, IYR

Seeking AlphaNov 30 01:31

Sector Update: Health Care Stocks Advance Pre-Bell Friday

MT NewswiresNov 29 22:17

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Ahead of US Farm Prices Data

MT NewswiresNov 29 21:18

How to adjust the new national medical insurance catalog? Here is the explanation.

1. The success rate is 76%, with an average decline of 63%. This year, the success rate and decline of negotiating/bidding pharmaceuticals are basically equivalent to previous years; 2. This year, the fund calculation will pay more attention to the impact on fund expenditure, while also enhancing the comprehensiveness and scientific nature of the calculation work; 3. This year's catalog adjustment places more emphasis on the actual clinical needs and patients' actual medication, highlighting support for true innovation.

cls.cnNov 28 21:54

RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330

BenzingaNov 28 01:02 · Ratings

Amgen Analyst Ratings

BenzingaNov 28 01:01 · Ratings

Sector Update: Health Care Stocks Rise Pre-Bell Wednesday

MT NewswiresNov 27 22:11

Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Ahead of Crucial Inflation Data

MT NewswiresNov 27 21:06

Trump Taps Jay Bhattacharya to Lead National Institutes of Health

Seeking AlphaNov 27 19:23